Search
Valvular heart disease is a major contributor to loss of physical function, quality of life and longevity. The epidemiology of VHD varies substantially around the world, with a predominance of functional and degenerative disease in high-income countries, and a predominance of rheumatic heart disease in low-income and middle-income countries. Reflecting this distribution, rheumatic heart disease remains by far the most common manifestation of VHD worldwide and affects approximately 41 million people.
Jonathan Jeffrey Carapetis AM Cannon AM MBBS FRACP FAFPHM PhD FAHMS BSc(Hons) BBus PhD Co-Head, Strep A Translation; Co-Founder of REACH Health
Indigenous children and young peoples live with an inequitable burden of acute rheumatic fever and rheumatic heart disease. In this Review, we focus on the epidemiological burden and lived experience of these conditions for Indigenous young peoples in Australia, New Zealand, and Canada. We outline the direct and indirect drivers of rheumatic heart disease risk and their mitigation.
These results indicate that anaphylaxis is not a major cause of adverse reactions to benzathine penicillin G
This report provides an update on the contemporary global and regional policy landscapes relevant to rheumatic heart disease
increased adherence to penicillin prophylaxis is associated with reduced acute rheumatic fever recurrence and a likely reduction in mortality
Population-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand
Health systems did not meet the needs of pregnant Aboriginal women with rheumatic heart disease
A multifaceted intervention was implemented using quality improvement and chronic care model approaches to improve delivery of penicillin prophylaxis for rheumatic heart disease
This strategy did not improve adherence to rheumatic heart disease secondary prophylaxis within the study time frame.